International Journal of Antimicrobial Agents
Volume 35, Issue 4 , Pages 375-381 , April 2010

Patterns of antimicrobial therapy in severe nosocomial infections: empiric choices, proportion of appropriate therapy, and adaptation rates—a multicentre, observational survey in critically ill patients

  • Dirk Vogelaers

      Affiliations

    • General Internal Medicine & Infectious Diseases, Ghent University Hospital, De Pintelaan 185, 9000 Ghent, Belgium
    • ,
  • David De Bels

      Affiliations

    • Intensive Care Department, Brugmann University Hospital, Brussels, Belgium
    • ,
  • Frédéric Forêt

      Affiliations

    • Department of Internal Medicine – Intensive Care Unit, CHR St. Joseph-Warquignies, Boussu, Belgium
    • ,
  • Sophie Cran

      Affiliations

    • Intensive Care Department, CHIREC, Brussels, Belgium
    • ,
  • Eric Gilbert

      Affiliations

    • Intensive Care Department, CHR du Tournaisis, Tournai, Belgium
    • ,
  • Karen Schoonheydt

      Affiliations

    • Intensive Care Department, Ziekenhuisnetwerk Antwerpen, Antwerp, Belgium
    • ,
  • Stijn Blot

      Affiliations

    • General Internal Medicine & Infectious Diseases, Ghent University Hospital, De Pintelaan 185, 9000 Ghent, Belgium
    • Corresponding Author InformationCorresponding author. Tel.: +32 9 332 62 16.
    • ,
  • for the ANTHICUS Study Investigators

      Affiliations

    • The ANTHICUS Study Investigators are: O. Abid (RHMS, Ath, Belgium), S. Cran (CHIREC, Brussels, Belgium), D. De Bels (CHU Brugmann, Brussels, Belgium), F. De Leener (CHR St. joseph-Warquignies, Boussu, Belgium), L. Finianos (Clinique St. Joseph, Liège, Belgium), F. Forêt (CHR St. Joseph-Warquignies, Mons, Belgium), M. Genard (CIU Ambroise Paré, Mons, Belgium), E. Gilbert (CHR du Tournaisis, Tournai, Belgium), E. Khodadadi (IRIS Sud-Bracops, Brussels, Belgium), S. Machayekhi (CH Hornu Frameries, Hornu), D. Mircev (IRIS Sud-Etterbeek-Ixelles, Brussels, Belgium), D. Neuberg (CH de L’Ardenne, Libramont, Belgium), J.-Y. Piette (CH Bois de l’Abbaye, Seraign, Belgium), P. Serpe (CH ND Bruyères, Chenee, Belgium), F. Beernaert (H. Hart Ziekenhuis, Eeklo, Belgium), K. De Decker (Antwerp University Hospital, Antwerp, Belgium), K. De Ridder (AZ Maria Middelares, Sint-Niklaas, Belgium), C. Declercq (St. Josef Ziekenhuis, Izegem, Belgium), I. Demeyer (OLV Aalst, Aalst, Belgium), B. Nonneman (ASZ, Aalst, Belgium), K. Schoonheydt (ZNA, Antwerp, Belgium, W. Swinnen (AZ St. Blasius, Dendermonde, Belgium), and L. Wosteyn (ASZ, Roeselaere, Belgium).

Received 17 September 2009 ,Accepted 23 November 2009.

References 

  1. Blot S. Limiting the attributable mortality of nosocomial infection and multidrug resistance in intensive care units. Clin Microbiol Infect. 2008;14:5–13
  2. Lorente L, Blot S, Rello J. Evidence on measures for the prevention of ventilator-associated pneumonia. Eur Respir J. 2007;30:1193–1207
  3. Masterton RG, Mifsud AJ, Rao GG. Review of hospital isolation and infection control precautions. J Hosp Infect. 2003;54:171–173
  4. Labeau SO, Vandijck DM, Rello J, Adam S, Rosa A, Wenisch C, et al. Centers for Disease Control and Prevention guidelines for preventing central venous catheter-related infection: results of a knowledge test among 3405 European intensive care nurses. Crit Care Med. 2009;37:320–323
  5. Labeau S, Vandijck D, Rello J, Adam S, Rosa A, Wenisch C, et al. Evidence-based guidelines for the prevention of ventilator-associated pneumonia: results of a knowledge test among European intensive care nurses. J Hosp Infect. 2008;70:180–185
  6. Yokoe DS, Classen D. Improving patient safety through infection control: a new healthcare imperative. Infect Control Hosp Epidemiol. 2008;29(Suppl. 1):S3–S11
  7. Berwick DM, Calkins DR, McCannon CJ, Hackbarth AD. The 100,000 lives campaign: setting a goal and a deadline for improving health care quality. JAMA. 2006;295:324–327
  8. van der Kooi TI, de Boer AS, Mannien J, Wille JC, Beaumont MT, Mooi BW, et al. Incidence and risk factors of device-associated infections and associated mortality at the intensive care in the Dutch surveillance system. Intensive Care Med. 2007;33:271–278
  9. Vincent JL, Bihari DJ, Suter PM, Bruining HA, White J, Nicolas-Chanoin MH, et al. The prevalence of nosocomial infection in intensive care units in Europe Results of the European Prevalence of Infection in Intensive Care (EPIC) Study. EPIC International Advisory Committee. JAMA. 1995;274:639–644
  10. Blot SI, Depuydt P, Annemans L, Benoit D, Hoste E, De Waele JJ, et al. Clinical and economic outcomes in critically ill patients with nosocomial catheter-related bloodstream infections. Clin Infect Dis. 2005;41:1591–1598
  11. Vander Stichele RH, Elseviers MM, Ferech M, Blot S, Goossens H. Hospital consumption of antibiotics in 15 European countries: results of the ESAC Retrospective Data Collection (1997–2002). J Antimicrob Chemother. 2006;58:159–167
  12. Vandijck DM, Depaemelaere M, Labeau SO, Depuydt PO, Annemans L, Buyle FM, et al. Daily cost of antimicrobial therapy in patients with Intensive Care Unit-acquired, laboratory-confirmed bloodstream infection. Int J Antimicrob Agents. 2008;31:161–165
  13. Safdar N, Dezfulian C, Collard HR, Saint S. Clinical and economic consequences of ventilator-associated pneumonia: a systematic review. Crit Care Med. 2005;33:2184–2193
  14. Blot S, Vandewoude K, Hoste E, Colardyn F. Reappraisal of attributable mortality in critically ill patients with nosocomial bacteraemia involving Pseudomonas aeruginosa. J Hosp Infect. 2003;53:18–24
  15. Blot S, Vandewoude K, Hoste E, De Waele J, Kint K, Rosiers F, et al. Absence of excess mortality in critically ill patients with nosocomial Escherichia coli bacteremia. Infect Control Hosp Epidemiol. 2003;24:912–915
  16. Garrouste-Orgeas M, Timsit JF, Tafflet M, Misset B, Zahar JR, Soufir L, et al. Excess risk of death from intensive care unit-acquired nosocomial bloodstream infections: a reappraisal. Clin Infect Dis. 2006;42:1118–1126
  17. Blot SI, Vandewoude KH, Colardyn FA. Clinical impact of nosocomial Klebsiella bacteremia in critically ill patients. Eur J Clin Microbiol Infect Dis. 2002;21:471–473
  18. Blot SI, Vandewoude KH, Colardyn FA. Evaluation of outcome in critically ill patients with nosocomial Enterobacter bacteremia: results of a matched cohort study. Chest. 2003;123:1208–1213
  19. Blot S, Cankurtaran M, Petrovic M, Vandijck D, Lizy C, Decruyenaere J, et al. Epidemiology and outcome of nosocomial bloodstream infection in elderly critically ill patients: a comparison between middle-aged, old, and very old patients. Crit Care Med. 2009;37:1634–1641
  20. Agbaht K, Diaz E, Munoz E, Lisboa T, Gomez F, Depuydt PO, et al. Bacteremia in patients with ventilator-associated pneumonia is associated with increased mortality: a study comparing bacteremic vs. nonbacteremic ventilator-associated pneumonia. Crit Care Med. 2007;35:2064–2070
  21. Vandewoude KH, Blot SI, Benoit D, Colardyn F, Vogelaers D. Invasive aspergillosis in critically ill patients: attributable mortality and excesses in length of ICU stay and ventilator dependence. J Hosp Infect. 2004;56:269–276
  22. Harbarth S, Garbino J, Pugin J, Romand JA, Lew D, Pittet D. Inappropriate initial antimicrobial therapy and its effect on survival in a clinical trial of immunomodulating therapy for severe sepsis. Am J Med. 2003;115:529–535
  23. Ibrahim EH, Sherman G, Ward S, Fraser VJ, Kollef MH. The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting. Chest. 2000;118:146–155
  24. Kollef MH, Sherman G, Ward S, Fraser VJ. Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients. Chest. 1999;115:462–474
  25. Kumar A, Roberts D, Wood KE, Light B, Parrillo JE, Sharma S, et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med. 2006;34:1589–1596
  26. Masterton R, Drusano G, Paterson DL, Park G. Appropriate antimicrobial treatment in nosocomial infections—the clinical challenges. J Hosp Infect. 2003;55(Suppl. 1):1–12
  27. Depuydt P, Benoit D, Vogelaers D, Claeys G, Verschraegen G, Vandewoude K, et al. Outcome in bacteremia associated with nosocomial pneumonia and the impact of pathogen prediction by tracheal surveillance cultures. Intensive Care Med. 2006;32:1773–1781
  28. Jung B, Sebbane M, Chanques G, Courouble P, Verzilli D, Perrigault PF, et al. Previous endotracheal aspirate allows guiding the initial treatment of ventilator-associated pneumonia. Intensive Care Med. 2009;35:101–107
  29. Depuydt P, Benoit D, Vogelaers D, Decruyenaere J, Vandijck D, Claeys G, et al. Systematic surveillance cultures as a tool to predict involvement of multidrug antibiotic resistant bacteria in ventilator-associated pneumonia. Intensive Care Med. 2008;34:675–682
  30. Blot S, Depuydt P, Vogelaers D, Decruyenaere J, De Waele J, Hoste E, et al. Colonization status and appropriate antibiotic therapy for nosocomial bacteremia caused by antibiotic-resistant Gram-negative bacteria in an intensive care unit. Infect Control Hosp Epidemiol. 2005;26:575–579
  31. Papadomichelakis E, Kontopidou F, Antoniadou A, Poulakou G, Koratzanis E, Kopterides P, et al. Screening for resistant Gram-negative microorganisms to guide empiric therapy of subsequent infection. Intensive Care Med. 2008;34:2169–2175
  32. Depuydt PO, Blot SI, Benoit DD, Claeys GW, Verschraegen GL, Vandewoude KH, et al. Antimicrobial resistance in nosocomial bloodstream infection associated with pneumonia and the value of systematic surveillance cultures in an adult intensive care unit. Crit Care Med. 2006;34:653–659
  33. Michel F, Franceschini B, Berger P, Arnal JM, Gainnier M, Sainty JM, et al. Early antibiotic treatment for BAL-confirmed ventilator-associated pneumonia: a role for routine endotracheal aspirate cultures. Chest. 2005;127:589–597
  34. Sandiumenge A, Diaz E, Bodí M, Rello J. Therapy of ventilator-associated pneumonia. A patients-based approach based on the ten rules of “The Tarragona Strategy”. Intensive Care Med. 2003;29:876–883
  35. Kollef MH. Hospital-acquired pneumonia and de-escalation of antimicrobial treatment. Crit Care Med. 2001;29:1473–1475
  36. Leone M, Garcin F, Bouvenot J, Boyadjev I, Visintini P, Albanese J, et al. Ventilator-associated pneumonia: breaking the vicious circle of antibiotic overuse. Crit Care Med. 2007;35:379–385[Quiz:86]
  37. Kollef M. Appropriate empirical antibacterial therapy for nosocomial infections: getting it right the first time. Drugs. 2003;63:2157–2168
  38. Kollef MH. Treatment of ventilator-associated pneumonia: get it right from the start. Crit Care Med. 2003;31:969–970
  39. Rello J, Vidaur L, Sandiumenge A, Rodriguez A, Gualis B, Boque C, et al. De-escalation therapy in ventilator-associated pneumonia. Crit Care Med. 2004;32:2183–2190
  40. Leone M, Martin C. How to break the vicious circle of antibiotic resistances?. Curr Opin Crit Care. 2008;14:587–592
  41. Masterton RG. The new treatment paradigm and the role of carbapenems. Int J Antimicrob Agents. 2009;33:105–110
  42. Calandra T, Cohen J. The international sepsis forum consensus conference on definitions of infection in the intensive care unit. Crit Care Med. 2005;33:1538–1548
  43. Blot S, Vandewoude K. Management of invasive candidiasis in critically ill patients. Drugs. 2004;64:2159–2175
  44. Vandewoude KH, Blot SI, Depuydt P, Benoit D, Temmerman W, Colardyn F, et al. Clinical relevance of Aspergillus isolation from respiratory tract samples in critically ill patients. Crit Care. 2006;10:R31
  45. Blot S, Vandewoude K, De Bacquer D, Colardyn F. Nosocomial bacteremia caused by antibiotic-resistant Gram-negative bacteria in critically ill patients: clinical outcome and length of hospitalization. Clin Infect Dis. 2002;34:1600–1606
  46. Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of disease classification system. Crit Care Med. 1985;13:818–829
  47. Giamarellos-Bourboulis EJ, Papadimitriou E, Galanakis N, Antonopoulou A, Tsaganos T, Kanellakopoulou K, et al. Multidrug resistance to antimicrobials as a predominant factor influencing patient survival. Int J Antimicrob Agents. 2006;27:476–481
  48. Leone M, Bourgoin A, Cambon S, Dubuc M, Albanese J, Martin C. Empirical antimicrobial therapy of septic shock patients: adequacy and impact on the outcome. Crit Care Med. 2003;31:462–467
  49. Ortega M, Marco F, Soriano A, Almela M, Martinez JA, Munoz A, et al. Analysis of 4758 Escherichia coli bacteraemia episodes: predictive factors for isolation of an antibiotic-resistant strain and their impact on the outcome. J Antimicrob Chemother. 2009;63:568–574
  50. Kollef KE, Schramm GE, Wills AR, Reichley RM, Micek ST, Kollef MH. Predictors of 30-day mortality and hospital costs in patients with ventilator-associated pneumonia attributed to potentially antibiotic-resistant gram-negative bacteria. Chest. 2008;134:281–287
  51. Albrecht SJ, Fishman NO, Kitchen J, Nachamkin I, Bilker WB, Hoegg C, et al. Reemergence of Gram-negative health care-associated bloodstream infections. Arch Intern Med. 2006;166:1289–1294
  52. Lautenbach E, Polk RE. Resistant gram-negative bacilli: a neglected healthcare crisis?. Am J Health Syst Pharm. 2007;64:S3–S21[Quiz: S2–4]
  53. Trouillet JL, Chastre J, Vuagnat A, Joly-Guillou ML, Combaux D, Dombret MC, et al. Ventilator-associated pneumonia caused by potentially drug-resistant bacteria. Am J Respir Crit Care Med. 1998;157:531–539
  54. De Gheldre Y, Glupczynski Y, Struelens M, De Mol P. Emergence of Enterobacter aerogenes as a major antibiotic-resistant nosocomial pathogen in Belgian hospitals. Clin Microbiol Infect. 1999;5:622–627
  55. De Gheldre Y, Struelens MJ, Glupczynski Y, De Mol P, Maes N, Nonhoff C, et al. National epidemiologic surveys of Enterobacter aerogenes in Belgian hospitals from 1996 to 1998. J Clin Microbiol. 2001;39:889–896
  56. Baran G, Erbay A, Bodur H, Onguru P, Akinci E, Balaban N, et al. Risk factors for nosocomial imipenem-resistant Acinetobacter baumannii infections. Int J Infect Dis. 2008;12:16–21
  57. Meyer E, Schwab F, Gastmeier P, Rueden H, Daschner FD, Jonas D. Stenotrophomonas maltophilia and antibiotic use in German intensive care units: data from Project SARI (Surveillance of Antimicrobial Use and Antimicrobial Resistance in German Intensive Care Units). J Hosp Infect. 2006;64:238–243
  58. Degoricija V, Sharma M, Legac A, Gradiser M, Sefer S, Vucicevic Z. Survival analysis of 314 episodes of sepsis in medical intensive care unit in university hospital: impact of intensive care unit performance and antimicrobial therapy. Croat Med J. 2006;47:385–397
  59. Dellinger RP, Carlet JM, Masur H, Gerlach H, Calandra T, Cohen J, et al. Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock. Intensive Care Med. 2004;30:536–555

PII: S0924-8579(09)00549-4

doi: 10.1016/j.ijantimicag.2009.11.015

International Journal of Antimicrobial Agents
Volume 35, Issue 4 , Pages 375-381 , April 2010

Article Tools

* Image Usage & Resolution